GATA2 rs2335052 Polymorphism Predicts the Survival of Patients with Colorectal Cancer

Xijuan Liu1☯, Beihai Jiang2☯, Aidong Wang3, Jiabo Di2, Zaozao Wang2, Lei Chen2, Xiangqian Su2*

1 Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Central Laboratory, Peking University Cancer Hospital & Institute, Beijing, China, 2 Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Minimally Invasive Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing, China

☯ These authors contributed equally to this work.
* suxiangqian@bjmu.edu.cn

Abstract

Background
GATA binding protein 2 (GATA2) is a transcription factor that has essential roles in hematologic malignancies and progression of various solid tumors. Our previous studies suggested that high GATA2 expression is associated with recurrence of colorectal cancer (CRC). However, the influence of GATA2 single nucleotide polymorphisms (SNPs) on the survival of CRC remains unknown.

Methods
We genotyped GATA2 SNP rs2335052 using Sanger sequencing after PCR amplification, and determined GATA2 expression by immunohistochemistry in a cohort of 180 CRC patients. Kaplan-Meier survival analysis and Cox proportional hazard regression were used to analyze the association between the GATA2 rs2335052 genotypes and the clinical outcome of CRC.

Results
We found that there was no significant correlation between the rs2335052 genotypes and the expression of GATA2. However, the Kaplan-Meier survival analysis suggested that the carriers of the A-allele of SNP rs2335052 were significantly associated with increased risk of recurrence and reduced disease-free survival (DFS), compared with those carrying the variant genotype of GG in rs2335052 (P = 0.021). Moreover, univariate and multivariate Cox regression analyses revealed that GATA2 SNP rs2335052 was an independent risk factor for the DFS of CRC patients.
Conclusion

Our results demonstrated that GATA2 SNP rs2335052 is an independent predictor for prognosis of CRC patients. This raised the possibility that SNP rs2335052 may serve as a potential indicator for predicting recurrence of CRC after curative colectomy.

Introduction

Colorectal cancer (CRC) is the third most prevalent cancer in the world and the second most common cause of cancer related death in the Western countries [1,2]. Data from the World Health Organization (WHO) shows that the incidence of CRC is rapidly increasing in many Asian countries including China [3]. Despite improvements in diagnosis, surgery, chemotherapy, and targeted therapy, the 5-year relative survival rate for patients with CRC still remains poor [4]. At present, the TNM staging system maintained by the American Joint Committee on Cancer (AJCC) is the most widely used guideline for staging and survival prediction [5]. However, the clinical outcomes of patients with CRC may vary considerably even within the same tumor stage, particularly of patients with stage II disease [6, 7]. Therefore, new molecular prognostic markers which could precisely stratify patients into different risk categories are clearly warranted.

GATA2 binding protein 2 (GATA2) is a zinc-finger transcription factor, which plays a crucial role in regulating transcription of genes involved in proliferation, development, and differentiation of hematopoietic cells [8–11]. There is growing evidence that altered GATA2 expression and constitutive heterozygous GATA2 mutation are associated with hematologic malignancies, as well as the development and progression of various solid tumors [12–20]. In sporadic and familial myeloid malignancies, high GATA2 expression and acquired or inherited mutations of the GATA2 gene have been reported [12–15]. For solid tumors, high levels of GATA2 expression are associated with poor prognosis and disease recurrence in prostate and CRC [16–18]. In addition, high GATA2 expression in non-cultured human breast carcinomas promotes the proliferation of breast cancer cells by inhibiting the transcription of PTEN [19]. However, Li et al reported that GATA2 expression was decreased in hepatocellular carcinoma tissues, and reduced expression of GATA2 correlated with poor prognosis of hepatocellular carcinoma [20]. These findings suggest that GATA2 may serve as a new predictor for the prognosis of different types of cancer.

GATA2 gene is located at chromosome 3q21. Many single nucleotide polymorphisms (SNPs) have been identified in human GATA2 gene, including rs2335052, rs3803, rs2713604, and so on [20–24]. These genetic variants may contribute to the altered expression and function of GATA2, and consequently, may have great influence on the clinical outcomes of CRC. However, the clinical significance of GATA2 SNPs in CRC has not been investigated yet.

In this study, we examined the SNP rs2335052 and the expression of GATA2 in a Chinese CRC cohort, and investigated the role of the GATA2 SNP rs2335052 as a predictor of the clinical outcome for CRC patients. Our results showed that although no significant correlation was observed between the rs2335052 genotypes and the expression of GATA2, the carriers of the A-allele of SNP rs2335052 showed a significant increased risk of recurrence and reduced disease-free survival (DFS). Thus, the GATA2 SNP rs2335052 may serve as a novel indicator for the prognosis of patients with CRC.
Materials and Methods

Ethics Statement

The study was approved and supervised by the research ethics committee of Peking University Cancer Hospital & Institute. Beijing, China. Written Informed Consents were obtained from all patients before surgery for general research using of their clinical data and specimens.

Patients

This retrospective study included 180 patients who were undergone colectomy at the Department of Minimally Invasive Gastrointestinal Surgery, and histologically diagnosed with CRC at the Department of Pathology at Peking University Cancer Hospital & Institute from April 2009 to December 2011. All tumors were graded by two experienced pathologists according to the American Joint Committee on Cancer (AJCC) classification guidelines. Patients treated with pre-operative radiotherapy or adjuvant chemotherapy were excluded. Sixteen patients with pathologically confirmed metastasis or died of complications were also excluded. Formalin-fixed paraffin embedded (FFPE) tissue samples of patients were available for the study. DFS was calculated as the time from cancer diagnosis to either relapse or death from the last follow up.

GATA2 SNP rs2335052 analysis

Genomic DNA was extracted from paraffin-embedded tumor specimens using FFPE DNA Kit (OMEGA, US) according to the manufacturer’s instructions. The GATA2 rs2335052 genotypes were determined by Sanger sequencing after amplification with polymerase chain reaction (PCR). The exon 3 of the GATA2 was amplified using the following primers: forward 5’-CCACCCTGATCCTCTCTCTTT and reverse 5’-TCACAGCTCCCCACCACAA. PCR was carried out in a 30μl volume, comprising 10–30ng genomic DNA, 0.2 mM dNTP, 1×PCR buffer, 10mM each primers, and 0.75 unit GoTaq DNA polymerase (Promega Cor., WI, USA) under the following amplification conditions: 2min at 95°C, followed by 35 cycles of 95°C for 30s, 60°C for 30 s, 72°C for 45 s. The PCR products were visualized on a 2% agarose gel and then subjected to direct sequencing. All fragments were sequenced using the ABI 3730XL Avant Genetic Analyzer (Applied Biosystems Inc., CA, USA). Finally, the sequencing results were analyzed with the Chromas software under the condition of signal/noise > 98%.

GATA2 immunohistochemistry (IHC)

IHC analysis for GATA2 was performed using a primary rabbit polyclonal antibody against GATA2 (1:100, Santa Cruz sc-9008), followed by incubation with a secondary antibody from the EnVision kit (Dako Cytomation). The visualization signal was developed with diaminobenzidine (Sigma). Sections were counterstained with hematoxylin. The staining intensity was scored as follows [18, 25]: -, no staining or <10% positive cells; +, 10–20% weakly to moderately positive cells; ++, 10–20% intensively positive cells or 20–50% weakly positive cells; and ++++, 20–50% positive cells with moderate to strong reactivity or >50% positive cells. The results reported by the two pathologists were highly consistent, and all disagreements were resolved by consensus after joint review. The score for GATA2 staining were described as either “low” or “high”, where “high” includes “++” and “++++” staining.

Statistical analysis

The association between GATA2 SNP rs2335052 and the clinicopathological characteristics were analyzed with Chi-squared test. Survival was determined using the Kaplan-Meier
methods and compared with the log-rank test. Univariate and multivariate survival analyses were performed using the Cox proportional hazard regression model. Fifteen patients lost to follow up were excluded in the Kaplan-Meier curve, univariate and multivariate analyses. The statistical analyses were performed with the software package SPSS 13.0 (SPSS, Inc., Chicago, IL, U.S.). P value of less than 0.05 was considered statistically significant.

Results

Patient characteristics and genotyping

A total of 180 samples from patients with CRC were analyzed. Median follow up time in the cohort was 69.0 months. Carriers of the rs2335052 GG, GA, and AA genotypes were 64 (35.6%), 81 (45.0%), and 35 (19.4%), respectively (Fig 1). Details of the clinical characteristics and GATA2 rs2335052 genotypes are shown in Table 1. GATA2 SNP rs2335052 was significantly associated with disease-free survival (DFS) of CRC (P = 0.033). However, no significant associations were observed between rs2335052 genotypes and other clinicopathological characteristics (all P-values > 0.05).

Association of GATA2 rs2335052 genotypes with DFS

Kaplan-Meier curves for DFS were graphically shown according to an additive, dominant, and recessive model of inheritance (Fig 2). The results revealed that SNP rs2335052 was
significantly associated with DFS under the dominant model of inheritance \((P = 0.021)\), which suggested that carriers of the A-allele of SNP rs2335052 (GA, AA) had a significantly increased risk of recurrence and reduced DFS (Fig 2B). The 5-year DFS rate of patients with carriers of the rs2335052 GA and AA genotypes was 69.0%, but for patients with carrier of the rs2335052 GG genotype, the rate was 92.0%. However, significant difference in DFS was not observed among GATA2 rs2335052 genotypes under the additive or recessive model \((P = 0.056, P = 0.834, \text{respectively, Fig 2A and 2C})\).

Additionally, we carried out a stratified analysis by the TNM stage (I/II and III/IV), to determine the prognostic significance of GATA2 rs2335052 genotypes in different tumor stages. Harboring rs2335052 GA or AA confirmed an adverse impact on DFS of stage I/II patients.

### Table 1. Clinicopathological features with respect to determined genotypes of included GATA2 SNP rs2335052.

| Characteristic                  | Cases (%) | GA (%) | GG (%) | AA (%) | \(P\)-value |
|--------------------------------|-----------|--------|--------|--------|-------------|
| **Age**                        |           |        |        |        |             |
| <60 yr                         | 77 (42.8) | 40 (49.4) | 23 (35.9) | 14 (40.0) | 0.249 |
| \(\geq\)60 yr                  | 103 (57.2) | 41 (50.6) | 41 (64.1) | 21 (60.0) |             |
| **Gender**                     |           |        |        |        |             |
| Female                         | 78 (43.3) | 30 (37.0) | 35 (54.7) | 13 (37.1) | 0.074 |
| Male                           | 102 (56.7) | 51 (63.0) | 29 (45.3) | 22 (62.9) |             |
| **Tumor location**             |           |        |        |        |             |
| Colon                          | 138 (76.7) | 65 (80.2) | 48 (75.0) | 25 (71.4) | 0.544 |
| Rectum                         | 42 (23.3) | 16 (19.8) | 16 (25.0) | 10 (28.6) |             |
| **Tumor size**                 |           |        |        |        |             |
| \(\leq\)4cm                    | 90 (50.3) | 44 (55.0) | 30 (46.9) | 16 (45.7) | 0.522 |
| \(>4\)cm                      | 89 (49.7) | 36 (45.0) | 34 (53.1) | 19 (54.3) |             |
| **Depth of invasion**          |           |        |        |        |             |
| T1/T2                          | 18 (10.0) | 9 (11.1) | 7 (10.9) | 2 (5.7) | 0.641 |
| T3/T4                          | 162 (90.0) | 72 (88.9) | 57 (89.1) | 33 (94.3) |             |
| **Lymph node involvement**     |           |        |        |        |             |
| Negative                       | 103 (57.2) | 48 (59.3) | 39 (60.9) | 16 (45.7) | 0.302 |
| Positive                       | 77 (42.8) | 33 (40.7) | 25 (39.1) | 19 (54.3) |             |
| **AJCC Stage**                 |           |        |        |        |             |
| I/II                           | 98 (54.4) | 45 (55.6) | 38 (59.4) | 15 (42.9) | 0.278 |
| III/IV                         | 82 (45.6) | 36 (44.4) | 26 (40.6) | 20 (57.1) |             |
| **Histological type**          |           |        |        |        |             |
| Adenocarcinoma                 | 168 (93.3) | 78 (96.3) | 59 (92.2) | 31 (88.6) | 0.279 |
| Mucinous                       | 12 (6.7) | 3 (3.7) | 5 (7.8) | 4 (11.4) |             |
| **Tumor differentiation**      |           |        |        |        |             |
| Well                            | 8 (4.8) | 4 (5.2) | 1 (1.7) | 3 (10.0) | 0.183 |
| Moderate                       | 150 (90.4) | 67 (87.0) | 56 (94.9) | 27 (90.0) |             |
| Poor                           | 8 (4.8) | 6 (7.8) | 2 (3.4) | 0 (0.0) |             |
| Unknown                        | 14 | | | | |
| **Chemotherapy**               |           |        |        |        |             |
| Not received                   | 93 (51.7) | 40 (49.4) | 36 (56.3) | 17 (48.6) | 0.656 |
| Received                       | 87 (48.3) | 41 (50.6) | 28 (43.8) | 18 (51.4) |             |
| **Disease-free Survival**      |           |        |        |        |             |
| Negative                       | 127 (76.5) | 53 (68.8) | 51 (87.9) | 23 (74.2) | 0.033 |
| Positive                       | 39 (23.5) | 24 (31.2) | 7 (12.1) | 8 (25.8) |             |
| **Overall Survival**           |           |        |        |        |             |
| Alive                          | 111 (67.3) | 52 (68.4) | 42 (72.4) | 17 (54.8) | 0.232 |
| Dead                           | 54 (32.7) | 24 (31.6) | 16 (27.6) | 14 (45.2) |             |
| Unknown                        | 15 | | | | |
| **GATA2 expression**           |           |        |        |        |             |
| Low                            | 71 (43.3) | 29 (39.7) | 29 (49.2) | 13 (40.6) | 0.523 |
| High                           | 93 (56.7) | 44 (60.3) | 30 (50.8) | 19 (59.4) |             |
| Unknown                        | 16 | | | | |

Differences in categorical study variables between genotypes were tested for statistical significance with the Chi-squared test. Tumors were classified according to the guidelines of the American Joint Committee on Cancer (AJCC) staging system.

doi:10.1371/journal.pone.0136020.t001
However, the GATA2 rs2335052 genotypes were not correlated with prognosis of patients with stage III/IV diseases ($P = 0.749$, Fig 3B).

The prognostic value of GATA2 rs2335052 genotypes in DFS was evaluated by univariate and multivariate Cox regression analyses using a dominant model of inheritance. As shown in Table 2, in both univariate and multivariate analyses, patients with the A-allele of SNP rs2335052 (GA, AA) had a shorter period of DFS, suggesting a higher risk of recurrence (HR, 2.530; 95% CI, 1.111–5.761; $P = 0.027$ and HR, 2.825; 95% CI, 1.095–7.290; $P = 0.032$, for univariate and multivariate analysis, respectively), compared with the patients with the SNP rs2335052 GG genotype. The results suggest that the GATA2 SNP rs2335052 was an independent prognostic factor for disease recurrence. The relative risk of recurrence in the patients

---

Fig 2. Kaplan-Meier analysis of DFS according to GATA2 SNP rs2335052. Kaplan-Meier curves are shown for an additive (A), dominant (B), and recessive model (C) of inheritance. The log-rank test was used to calculate $P$ values.

doi:10.1371/journal.pone.0136020.g002

Fig 3. Kaplan-Meier analysis for DFS according to rs2335052 genotypes in CRC patients stratified by clinical stage. Kaplan-Meier curves indicated DFS for the subgroup of patients with stage I/II (A), and stage III/IV (B) CRC. The log-rank test was used to calculate $P$ values.

doi:10.1371/journal.pone.0136020.g003
with rs2335052 GA and AA genotypes was 2.825-fold higher than that of the patients with the rs2335052 GG genotype, according to the multivariate analysis. Unfavorable survival outcomes were also significantly associated with male patients, stage III/IV CRC and poor or moderate tumor differentiation, based on univariate analysis (Table 2).

### Association between GATA2 rs2335052 genotypes and GATA2 expression

The expression of GATA2 was examined in 164 of 180 CRC tissues (Fig 4). High GATA2 expression was detected in 93 out of 164 (56.7%) CRC tissues, compared with 7 out of 97 (7.2%) in matched adjacent noncancerous tissues ($P < 0.0001$). Kaplan-Meier curve for DFS showed that patients with tumors exhibiting high GATA2 expression had worse prognosis, suggesting shorter DFS and earlier disease recurrence ($P = 0.044$, Fig 5A). However, no significant association was observed between GATA2 expression and SNP rs2335052 ($P = 0.523$, Table 1).

Since SNP rs2335052 GG genotype showed a significant protective influence on DFS in the dominant model of inheritance (Fig 2B), for further analysis, patients were divided into two groups according to their rs2335052 genotypes (GG subgroup, GA and AA subgroup). In the rs2335052 GG subgroup, high levels of GATA2 expression showed borderline significant association with shorter DFS, compared with low GATA2 expression ($P = 0.073$, Fig 5B). However,
there was no significant association between the levels of GATA2 expression and DFS in the subgroup of patients carrying the rs2335052 GA and AA genotypes ($P = 0.208$, Fig 5C).

**Discussion**

In this study, we investigated the association between the GATA2 SNP rs2335052 and the prognosis of CRC patients in a Chinese cohort. Our data revealed that although there was no significant correlation between the rs2335052 genotypes and the expression of GATA2, the rs2335052 GA and AA genotypes were significantly associated with unfavorable prognosis and increased risk of recurrence in patients with CRC, compared with those carrying the GG genotype. Moreover, univariate and multivariate Cox regression analysis demonstrated that the rs2335052 SNP in GATA2 was an independent predictor for poor DFS in CRC patients.

Several previous studies have demonstrated the influence of GATA2 expression levels on the clinical outcome in patients with pediatric acute myeloid leukemia (AML), colorectal, prostate, breast cancer, and hepatocellular carcinoma [14, 16–20]. Except hepatocellular carcinoma [20], high levels of GATA2 expression indicate tumor recurrence, metastasis, or poor survival [14, 16–19]. Besides the protein level of GATA2, the genetic diversity of the GATA2 locus also influences tumorigenesis. Acquired and inherited mutations in GATA2 have been reported to be correlated with myeloid malignancies including AML, and chronic myeloid leukemia (CML) [13–15]. Rearrangement of the GATA2 enhancer to EVI1 causes reduced and monoallelic expression of GATA2, as well as activation of EVI1 in sporadic familial AML/MDS and MonoMac/Emberger syndromes [26]. However, the role of GATA2 genotypes in cancer prognosis remains largely unexplored in solid tumors. Since SNPs locate in the coding and regulatory sequences of GATA2, they may contribute to the regulation of GATA2 expression and function, so we investigated the GATA2 SNP genotypes.

According to the NCBI SNP database, there are several SNPs located at the GATA2 locus. We first sequenced the whole exon of GATA2 in 23 CRC tissues, in order to identify SNPs of potential interest. Our results showed that SNP rs2335052 could be detected in the third exon of GATA2 gene among the 23 CRC tissues, although other genetic variants were absent, probably due to limited sample size (S1 Table). Then, we determined the GATA2 SNP rs2335052...
and the expression of GATA2 in a CRC cohort consisting of 180 patients, and investigated the influence of the SNP rs2335052 on patient survival. The results indicated that GATA2 rs2335052 GA and AA genotypes are significantly associated with reduced DFS and recurrence in CRC patients. In addition, the analysis of a replication cohort of 61 CRC patients also suggested that GATA2 SNP rs2335052 was an independent predictor for poor DFS in CRC patients (S2 and S3 Tables, S1 Fig).

Several studies have shown that being a transcription factor, GATA2 acts as a key regulator in many signaling pathways. In KRAS mutant non-small cell lung cancer (NSCLC), GATA2 is involved in the regulation of the proteasome, IL-1-signaling, and Rho-signaling pathways. As a result, GATA2 is indispensable for the survival of NSCLC cells with RAS-pathway mutations [27, 28]. In prostate cancer, GATA2 plays a crucial role in mediating androgen receptor (AR) expression, as well as in site-specific AR recruitment facilitating AR target gene expression [29]. In breast cancer, GATA2 promotes cell proliferation and stimulates AKT phosphorylation by inhibiting PTEN transcription [19]. These raise the possibility of regulating GATA2-involved pathways for cancer therapeutic strategies [27, 28]. Similarly, SNPs that are associated with GATA2 function and clinical outcomes may serve as easily detectable predictors in GATA2-related treatment in the future.

Moreover, as a transcription factor, small genetic alterations in GATA2 may contribute to the regulation of downstream genes. The variant rs2335052 is located within the coding region of GATA2, leading to a substitution of alanine to threonine at codon 164 (A164T) in the third exon. The change of this amino acid is not located at zinc finger regions, which play important roles in GATA2 binding to DNA. To understand the underlying mechanisms involved in the prognostic value of GATA2 SNP rs2335052 on DFS, we predicted the function of GATA2 with amino acid substitute (GATA2-A164T) by Polymorphism Phenotyping v2 (PolyPhen-2), SIFT, and Pmut softwares, which are available via the websites, and determined the transactivation ability of GATA2-A164T by luciferase reporter assays. Although the software-predicted results showed that A164T does not predict potential pathological impact on the function of GATA2 (S2 Fig), the results of luciferase reporter assays suggested that GATA2-A164T reduced the transactivation ability compared to wild type GATA2 (GATA2wt) on the known GATA2-responsive LYL1 promoter [30]. In addition, decreased GATA2-A164T expression was observed in CRC cell lines (S1 File, S4 Table, S3 Fig). These data raised the possibility that GATA2-A164T affect the expression or function of downstream genes which are associated with the survival of CRC patients. Although, in this study, no significant association was found between GATA2 rs2335052 genotype and gene expression in the patient cohort, the decreased expression and reduced transactivation ability of GATA2 A164T, compared with wild type GATA2, indicate that reduced GATA2 expression may contribute to decreased disease-free survival (DFS). Inconsistently, in this study and our previous study, decreased GATA2 expression was associated with better survival in patients with CRC.

Similarly, many studies reported that although variant genotype may regulate the expression level of that gene, the association between the polymorphisms and survival may be inconsistent with the association between the gene expression and survival [31–34]. For example, patients with wild type AA genotype in ABCC1 rs35628 had longer DFS than patients carrying the G allele. Tumors from carriers of the AA genotype expressed significantly higher ABCC1 than those with the G allele. These data raised the possibility that high expression of ABCC1 may contribute to prolonged survival. In contrast, high expression levels of ABCC1 indicates poor prognosis for breast carcinoma [31, 32]. In addition, patients with VV genotype in NPAS2 rs1053090 conferred a significantly increased risk of death, compared with those with WW and VW genotype. Patients carrying the VV genotype also showed a significantly higher expression level of NPAS2. However, high level of NPAS2 expression was significantly
correlated with better DFS [33, 34]. Therefore, other molecular consequences of genetic variation of SNP rs2335052 may exist.

CRC Patients within the same TNM stage may show considerably different clinical outcomes, particularly in stage II disease [6, 7]. The use of adjuvant therapy for stage II CRC patients remains controversial [35–38]. Thus, in order to determine whether SNP rs2335052 in GATA2 could be used to identify patients with a high risk of recurrence so that they may receive further chemotherapy, the role of SNP rs2335052 on DFS and recurrence was evaluated. In the current cohort, among the patients with stage I/II diseases, rs2335052 GA and AA genotypes suggest poor clinical outcome and recurrence, compared with the GG genotype. Our results provided GATA2 SNP rs2335052 as a prognostic factor independent of tumor stages, and raise the possibility to identify patients with higher risk of recurrence and should be treated with adjuvant chemotherapy.

However, there are potential limitations of this study. The cohort in our study is of moderate sample size. Therefore, additional studies with larger independent populations are needed to further validate the association of the GATA2 SNP rs2335052 with the clinical outcome of CRC patients.

Conclusions
In conclusion, our study demonstrated that SNP rs2335052 in GATA2 is associated with DFS and recurrence of CRC patients. The results of our study suggested that SNP rs2335052 is an independent indicator for predicting the prognosis of CRC in Chinese population. Further studies are needed to validate these findings and clarify the underlying mechanism.

Supporting Information
S1 Fig. Kaplan-Meier analysis of DFS according to GATA2 SNP rs2335052 in another cohort including 61 CRC patients. Kaplan-Meier curves are shown for an additive (A), dominant (B), and recessive model (C) of inheritance. The log-rank test was used to calculate P values.
(TIF)

S2 Fig. Results of the software analysis for alanine to threonine substitution (A164T) of GATA2 SNP rs2335052. A164T did not predict potential pathological impact on the function or structure of GATA2, by using PolyPhen-2 (A), SIFT (B), and Pmut (C), which are available via the websites.
(TIF)

S3 Fig. GATA2-A164T reduced the transactivation ability on the LYL1 promoter. (A) Western blot analysis of exogenous FLAG-GATA2 expression in RKO cells transfected with plasmid encoding GATA2wt or GATA2-A164T. (B) Luciferase reporter assay demonstrated that GATA2-A164T reduced the transactivation ability on the known GATA2-responsive LYL1 promoter, compared with GATA2wt. The data represent the mean ± SD of three independent experiments in triplicate of each sample. In all comparisons, a Student’s t-test was used.
(TIF)

S1 File. Materials and Methods.
(DOC)

S1 Table. All the polymorphisms analyzed in the 23 CRC tissues.
(DOCX)
Acknowledgments
We thank Dr. Bin Dong and Dr. Zhongwu Li for histopathological diagnosis.

Author Contributions
Conceived and designed the experiments: XS BJ. Performed the experiments: XL BJ AW LC. Analyzed the data: XL BJ. Contributed reagents/materials/analysis tools: AW ZW. Wrote the paper: BJ XL JD XS.

References
1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2014; 64: 252–71. doi:10.3322/caac.21235 PMID:24890451
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010; 375: 1030–47. doi: 10.1016/S0140-6736(10)60353-4 PMID:20304247
3. Ng SC, Wong SH. Colorectal cancer screening in Asia. Br Med Bull. 2013; 105: 29–42. doi: 10.1093/bmb/lds040 PMID:23299409
4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212–36. doi: 10.3322/caac.20121 PMID:21685461
5. Edgen S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual (7th Edition). New York: Springer; 2010.
6. Weiser MR, Landmann RG, Kattan MW, Gonén M, Shia J, Chou J, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008; 26: 380–5. doi: 10.1200/JCO.2007.14.1291 PMID:18202413
7. Weiser MR, Gönen M, Chou JF, Kattan MW, Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol. 2011; 29: 4796–802. doi:10.1200/JCO.2011.36.5080 PMID:22084366
8. Evans T, Reitman M, Felsenfeld G. An erythrocyte-specific DNA-binding factor recognizes a regulatory sequence common to all chicken globin genes. Proc Natl Acad Sci USA. 1988; 85: 5976–80. PMID:3413070
9. Tsai SF, Martin DI, Zon LI, D’Andrea AD, Wong GG, Orkin SH. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature. 1989; 339: 446–51. PMID:2725678
10. Gilliland DG. Hematologic malignancies. Curr Opin Hematol. 2001; 8: 189–91. PMID:11561153
11. Vicente C, Conchillo A, García-Sánchez MA, Otero MD. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol. 2012; 82:1–17. doi:10.1016/j.critrevonc.2011.04.007 PMID:21605981
12. Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, et al. The evolution of cellular deficiency in GATA2 mutation. Blood. 2014; 123: 863–74. doi: 10.1182/blood-2013-07-517151 PMID:24345756
13. Pasquet M, Bellanné-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, et al. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood. 2013; 121: 822–9. doi: 10.1182/blood-2012-08-447367 PMID:23229431
14. Luesink M, Hollink IH, van der Velden VH, Knops RH, Boezeman JB, de Haas V, et al. High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Blood. 2012; 120: 2064–75. doi: 10.1182/blood-2011-397083 PMID: 22786876

15. Zhang SJ, Ma LY, Huang QH, Li G, Gu BW, Gao XD, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2008; 105: 2076–81. doi: 10.1073/pnas.0711824105 PMID: 18250304

16. Böhm M, Locke WJ, Sutherland RL, Kench JG, Henshall SM. A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene. 2009; 28: 3847–56. doi: 10.1038/onc.2009.243 PMID: 19864615

17. Chiang YT, Wang K, Fazli L, Gleave ME, Collins CC, et al. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget. 2014; 5: 451–61. PMID: 24448935

18. Chen L, Jiang B, Wang Z, Liu M, Ma Y, Yang H, et al. Expression and prognostic significance of GATA-2 in colorectal cancer. Med Oncol. 2013; 30: 498. doi: 10.1007/s12032-013-0498-7 PMID: 23423786

19. Wang Y, He X, Ngeow J, Eng C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet. 2012; 21: 569–76. doi: 10.1093/hmg/ddr491 PMID: 22021428

20. Li YW, Wang JX, Yin X, Qiu SJ, Wu H, Liao R, et al. Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma. PLoS One. 2014; 9: e87505. doi: 10.1371/journal.pone.0087505 PMID: 24498120

21. Muiya NP, Waki S, Al-Najai M, Tahir AI, Baz B, Andres E, et al. A study of the role of GATA2 gene polymorphism in coronary artery disease risk traits. Gene. 2014; 544: 152–8. doi: 10.1016/j.gene.2014.04.064 PMID: 24786211

22. Liu YH, Zhou YW, Yang JA, Tu ZG, Ji SY, Huang ZY, et al. Gene polymorphisms associated with susceptibility to coronary artery disease in Han Chinese people. Genet Mol Res. 2014; 13: 2619–27. doi: 10.4238/2014.April.8.4 PMID: 24782050

23. Kurzawski M, Bialecka M, Slawek J, Klodowska-Duda G, Dro dzik M. Association study of GATA-2 transcription factor gene (GATA2) polymorphism and Parkinson's disease. Parkinsonism Relat Disord. 2010; 16: 284–7. doi: 10.1016/j.parkreldis.2009.10.006 PMID: 19864173

24. Horne BD, Hauser ER, Wang L, Muhlestein JB, Anderson JL, Carlquist JF, et al. Validation study of genetic associations with coronary artery disease on chromosome 3q13–21 and potential effect modification by smoking. Ann Hum Genet. 2009; 73: 551–8. doi: 10.1111/j.1469-1809.2009.00540.x PMID: 19706030

25. Xing X, Peng L, Qu L, Ren T, Dong B, Su X, et al. Prognostic value of PRL-3 overexpression in early stages of colonic cancer. Histopathology. 2009; 54: 309–18. doi: 10.1111/j.1365-2559.2009.03226.x PMID: 19236507

26. Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014; 157: 369–81. doi: 10.1016/j.cell.2014.02.019 PMID: 24703711

27. Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 2012; 149: 642–55. doi: 10.1016/j.cell.2012.02.059 PMID: 22541434

28. Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 2012; 22: 1227–45. doi: 10.1038/cr.2012.82 PMID: 22613949

29. Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, et al. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res. 2014; 42: 3607–22. doi: 10.1093/nar/gkt1382 PMID: 24423874

30. Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011; 43: 1012–7. doi: 10.1038/ng.913 PMID: 21892162

31. Kunická T, Václavíková R, Hlaváč V, Vrána D, Pecha V, Rauš K, et al. Non-coding polymorphisms in nucleotide binding domain 1 in ABC11 gene associate with transcript level and survival of patients with breast cancer. PLoS One. 2014; 9: e101740. doi: 10.1371/journal.pone.0101740 PMID: 25078270

32. Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, et al. High expression of ATP-binding cassette transporter ABC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat. 2013; 137: 773–82. doi: 10.1007/s10549-012-2398-5 PMID: 23288347
33. Yuan P, Wang S, Zhou F, Wan S, Yang Y, Huang X, et al. Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization-treated hepatocellular carcinoma patients. Cancer Sci. 2014; 105: 825–32. doi:10.1111/cas.12428 PMID: 24754267

34. Yi C, Mu L, de la Longrais IA, Sochirca O, Arisio R, Yu H, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat. 2010; 120: 663–9. doi:10.1007/s10549-009-0484-0 PMID: 19649706

35. Yu X, McBean AM. Screening mammography use and chemotherapy among female stage II colon cancer patients: a retrospective cohort study. BMC Health Serv Res. 2010; 10: 98. doi:10.1186/1472-6963-10-98 PMID: 20403187

36. Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2014; 22: 3408–19.

37. Morris M, Platell C, McCaul K, Millward M, van Hazel G, Bayliss E, et al. Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis. 2007; 22: 887–95. PMID: 17235506

38. Jonker DJ, Spithoff K, Maroun J. Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol). 2011; 23: 314–22.